1
|
Dietz M, Jacquet-Francillon N, Bani Sadr A, Collette B, Mure PY, Demède D, Pina-Jomir G, Moreau-Triby C, Grégoire B, Mouriquand P, Janier M, Flaus A. Ultrafast cadmium-zinc-telluride-based renal single-photon emission computed tomography: clinical validation. Pediatr Radiol 2023; 53:1911-1918. [PMID: 37171639 PMCID: PMC10421805 DOI: 10.1007/s00247-023-05682-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 04/13/2023] [Accepted: 04/14/2023] [Indexed: 05/13/2023]
Abstract
BACKGROUND One of the main limitations of 99mtechnetium-dimercaptosuccinic acid (DMSA) scan is the long acquisition time. OBJECTIVE To evaluate the feasibility of short DMSA scan acquisition times using a cadmium-zinc-telluride-based single-photon emission computed tomography (SPECT) system in children. MATERIALS AND METHODS The data of 27 children (median age: 4 years; 16 girls) who underwent DMSA SPECT were retrospectively analyzed. Both planar and SPECT DMSA were performed. SPECT images were analyzed using coronal-simulated planar two-dimensional images. A reduction in SPECT acquisition time was simulated to provide 4 series (SPECT-15 min, SPECT-10 min, SPECT-5 min and SPECT-2.5 min). A direct comparison of the planar and SPECT series was performed, including semi-quantification reproducibility, image quality (mean quality score on a scale of 0 to 2) and inter- and intra-observer reproducibility of the scintigraphic patterns. RESULTS The overall image quality score (± standard deviation) was 1.3 (± 0.6) for the planar data set, 1.6 (± 0.5) for the SPECT-15 min data set, 1.4 (± 0.5) for the SPECT-10 min data set, 1.0 (± 0.5) for the SPECT-5 min data set and 0.6 (± 0.6) for the SPECT-2.5 min data set. Median Kappa coefficients for inter-observer agreement between planar and SPECT images were greater than 0.83 for all series and all readers except one reader for the SPECT-2.5 min series (median Kappa coefficient = 0.77). CONCLUSION Shortening SPECT acquisitions to 5 min is feasible with minimal impact on images in terms of quality and reproducibility.
Collapse
Affiliation(s)
- Matthieu Dietz
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France.
- INSERM U1060, CarMeN Laboratory, University of Lyon, Lyon, France.
| | | | - Alexandre Bani Sadr
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Boris Collette
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Pierre-Yves Mure
- Service de Chirurgie Pédiatrique (Urologique, Thoracique et Transplantation), Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - Delphine Demède
- Service de Chirurgie Pédiatrique (Urologique, Thoracique et Transplantation), Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - Géraldine Pina-Jomir
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Caroline Moreau-Triby
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Bastien Grégoire
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Pierre Mouriquand
- Service de Chirurgie Pédiatrique (Urologique, Thoracique et Transplantation), Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
| | - Marc Janier
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
| | - Anthime Flaus
- Service de Médecine Nucléaire, Hospices Civils de Lyon, 59 Bvd Pinel, 69634, Lyon, France
- Lyon Neuroscience Research Center, UMR5292, INSERM U1028/CNRS, Lyon, France
| |
Collapse
|
2
|
Duval X, Le Moing V, Tubiana S, Esposito-Farèse M, Ilic-Habensus E, Leclercq F, Bourdon A, Goehringer F, Selton-Suty C, Chevalier E, Boutoille D, Piriou N, Le Tourneau T, Chirouze C, Seronde MF, Morel O, Piroth L, Eicher JC, Humbert O, Revest M, Thébault E, Devillers A, Delahaye F, Boibieux A, Grégoire B, Hoen B, Laouenan C, Iung B, Rouzet F. Impact of Systematic Whole-body 18F-Fluorodeoxyglucose PET/CT on the Management of Patients Suspected of Infective Endocarditis: The Prospective Multicenter TEPvENDO Study. Clin Infect Dis 2021; 73:393-403. [PMID: 32488236 DOI: 10.1093/cid/ciaa666] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Accepted: 05/27/2020] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Diagnostic and patients' management modifications induced by whole-body 18F-FDG-PET/CT had not been evaluated so far in prosthetic valve (PV) or native valve (NV) infective endocarditis (IE)-suspected patients. METHODS In sum, 140 consecutive patients in 8 tertiary care hospitals underwent 18F-FDG-PET/CT. ESC-2015-modified Duke criteria and patients' management plan were established jointly by 2 experts before 18F-FDG-PET/CT. The same experts reestablished Duke classification and patients' management plan immediately after qualitative interpretation of 18F-FDG-PET/CT. A 6-month final Duke classification was established. RESULTS Among the 70 PV and 70 NV patients, 34 and 46 were classified as definite IE before 18F-FDG-PET/CT. Abnormal perivalvular 18F-FDG uptake was recorded in 67.2% PV and 24.3% NV patients respectively (P < .001) and extracardiac uptake in 44.3% PV and 51.4% NV patients. IE classification was modified in 24.3% and 5.7% patients (P = .005) (net reclassification index 20% and 4.3%). Patients' managements were modified in 21.4% PV and 31.4% NV patients (P = .25). It was mainly due to perivalvular uptake in PV patients and to extra-cardiac uptake in NV patients and consisted in surgery plan modifications in 7 patients, antibiotic plan modifications in 22 patients and both in 5 patients. Altogether, 18F-FDG-PET/CT modified classification and/or care in 40% of the patients (95% confidence interval: 32-48), which was most likely to occur in those with a noncontributing echocardiography (P < .001) or IE classified as possible at baseline (P = .04), while there was no difference between NV and PV. CONCLUSIONS Systematic 18F-FDG-PET/CT did significantly and appropriately impact diagnostic classification and/or IE management in PV and NV-IE suspected patients. CLINICAL TRIALS REGISTRATION NCT02287792.
Collapse
Affiliation(s)
- Xavier Duval
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,INSERM UMR-1137 IAME, Paris, France.,University Paris Diderot, Paris 7, UFR de Médecine-Bichat, Paris, France
| | - Vincent Le Moing
- Department of Infectious Diseases, University Hospital of Montpellier, Montpellier, France
| | - Sarah Tubiana
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,INSERM UMR-1137 IAME, Paris, France
| | - Marina Esposito-Farèse
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,Unité de Recherche Clinique, AP-HP, HUPNVS, Hôpital Universitaire Paris Nord-Val de Seine, Paris, France
| | - Emila Ilic-Habensus
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France
| | - Florence Leclercq
- Department of Cardiology, University Hospital of Montpellier, Montpellier, France
| | - Aurélie Bourdon
- Department of Nuclear Medicine, University Hospital of Montpellier, Montpellier, France
| | - François Goehringer
- Department of Infectious Diseases, University Hospital of Nancy, Nancy, France
| | | | - Elodie Chevalier
- Department of Nuclear Medicine, University Hospital of Nancy, Nancy, France
| | - David Boutoille
- Department of Infectious Diseases, CIC UIC 1413 INSERM, University Hospital of Nantes, Nantes, France
| | - Nicolas Piriou
- Thorax Institute, INSERM, UMR 1087, University Hospital of Nantes, Nantes, France.,Department of Nuclear Medicine, Nantes University Hospital, G. et R. Laennec Hospital, Nantes, France
| | - Thierry Le Tourneau
- Thorax Institute, INSERM, UMR 1087, University Hospital of Nantes, Nantes, France
| | - Catherine Chirouze
- University Hospital of Besançon, France, UMR CNRS 6249 Chrono-Environnement, Bourgogne University, Franche-Comté, Dijon, France
| | | | - Olivier Morel
- Department of Nuclear Medicine, University Hospital of Besançon, Besançon, France
| | - Lionel Piroth
- Department of Infectious Diseases, University Hospital of Dijon, INSERM CIC 1432, CHU Dijon, France
| | | | - Olivier Humbert
- Department of Nuclear Medicine, University Hospital of Dijon, Dijon, France
| | - Matthieu Revest
- Infectious Diseases and Intensive Care Unit, University Hospital of Rennes France, INSERM U1230 CHU Rennes, France.,INSERM CIC 1414, University Hospital of Rennes, France
| | | | - Anne Devillers
- Department of Nuclear Medicine, University Hospital of Rennes, France
| | | | - André Boibieux
- Department of Nuclear Medicine, University Hospital of Lyon, Lyon, France
| | - Bastien Grégoire
- Department of Infectious Diseases, University Hospital of Lyon, Lyon, France
| | - Bruno Hoen
- Department of Infectious Diseases, University Hospital of Nancy, Nancy, France
| | - Cédric Laouenan
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,INSERM UMR-1137 IAME, Paris, France.,University Paris Diderot, Paris 7, UFR de Médecine-Bichat, Paris, France.,Unité de Recherche Clinique, AP-HP, HUPNVS, Hôpital Universitaire Paris Nord-Val de Seine, Paris, France
| | - Bernard Iung
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,INSERM UMR-1137 IAME, Paris, France.,University Paris Diderot, Paris 7, UFR de Médecine-Bichat, Paris, France
| | - François Rouzet
- INSERM CIC 1425, Paris, France.,AP-HP, University Hospital of Bichat, Paris, France.,INSERM UMR-1137 IAME, Paris, France.,University Paris Diderot, Paris 7, UFR de Médecine-Bichat, Paris, France.,Department of Nuclear Medicine, AP-HP, University Hospital of Bichat, Paris, France
| | | |
Collapse
|